IN THE CLAIMS

The claims are as follows:

- (Cancelled)
- (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antisense nucleic acid is about 20 nucleotides in length.
- (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antisense nucleic acid sequence is phosphorothiolated.
- 4. (Cancelled)
- (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is catalase or phospholipid glutathione peroxidase.
- 6. (Previously Presented) An oligonucleotide comprising an antisense nucleic acid sequence that is about 18 to 26 nucleotides in length, is at least 90% complementary to and is capable of specifically binding to a contiguous portion of a nucleic acid that encodes a human antioxidant enzyme selected from the group consisting of manganese superoxide dismutase, copper and zinc superoxide dismutase, catalase, phospholipid glutathione peroxidase, and cytosolic glutathione peroxidase; wherein the contiguous portion includes the start codon of the nucleic acid encoding the human antioxidant enzyme.
- 7. (Previously Presented) An oligonucleotide comprising an antisense nucleic acid sequence that is about 18 to 26 nucleotides in length, is 100% complementary to and is capable of specifically binding to a contiguous portion of a nucleic acid that encodes a human antioxidant enzyme selected from the group consisting of manganese superoxide dismutase, copper and zinc

superoxide dismutase, catalase, phospholipid glutathione peroxidase, and cytosolic glutathione peroxidase; wherein the contiguous portion includes the start codon of the nucleic acid encoding

the human antioxidant enzyme.

8. (Previously Presented) A method of treating a tumor in a mammal comprising reducing

antioxidant enzyme levels in a cell by administering a therapeutic agent comprising an antisense

nucleic acid sequence that is about 18 to 26 nucleotides in length and is capable of specifically

binding to a contiguous portion of a nucleic acid that encodes a human manganese superoxide dismutase, and wherein the contiguous portion includes the start codon of the nucleic acid

encoding the human manganese superoxide dismutase.

9-10. (Cancelled)

11. (Previously presented) The method of claim 8, wherein the therapeutic agent is injected

into the tumor.

12. (Original) The method of claim 8, wherein the mammal is a human.

13. (Original) The method of claim 8, wherein the therapeutic agent further comprises a

delivery vehicle.

14. (Original) The method of claim 13, wherein the delivery vehicle is lipofectamine or -[1-

 $(2,3-dioleoyloxy) propyl]-{\it N,N,N-} trimethy lammonium methyl sulfate ("DOTAP").$

15. (Previously Presented) The method of claim 8, wherein the antisense nucleic acid

sequence is phosphorothiolated.

16-17. (Cancelled)

Title: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING ANTISENSE OLIGONUCLEOTIDES

- 18. (Previously Presented) The method of claim 8, wherein the antisense nucleic acid sequence is 90% complementary to a the portion of the nucleic acid for the antioxidant enzyme.
- 19 (Previously Presented) The method of claim 8, wherein the antisense nucleic acid sequence is 100% complementary to a the portion of the nucleic acid for the antioxidant enzyme.
- 20. (Previously Presented) An oligonucleotide comprising an antisense nucleic acid sequence that specifically binds to a nucleic acid encoding an antioxidant enzyme start codon, wherein the sequence is SEO ID NO:2.
- 21. (Previously Presented) The oligonucleotide of claim 20, wherein the antisense nucleic acid sequence is phosphorothiolated.
- 22. (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is manganese superoxide dismutase.
- 23. (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is copper and zinc superoxide dismutase.
- 24. (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is catalase.
- 25. (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is phospholipid glutathione peroxidase.
- 26. (Previously Presented) The oligonucleotide of claim 6 or 7, wherein the antioxidant enzyme is cytosolic glutathione peroxidase.